Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Related Articles
Sarcoma Updates from ESMO 2024: Insights from Dr. Herbert Loong
Herbert Loong, Clinical Associate Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, discusses key sarcoma updates from…
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.
Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis
Aaron Gerds, MD, discusses differences in molecular targets, efficacy, and toxicity profiles between available JAK inhibitors in myelofibrosis.
Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT
Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies undergoing allo-HCT.
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.
Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Robotic Partial Cystectomy Safe After Neoadjuvant Chemotherapy for MIBC – Oncology Nurse Advisor
Small retrospective study showed that the procedure achieved negative surgical margins in all cases, with no patients requiring salvage cystectomy.
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
